Company news

Kura Oncology, Inc. news in 2024

Kura Oncology, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

December 8, 2024

Kura Oncology to Host Virtual Investor Event on December 9, 2024

December 1, 2024

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

November 24, 2024

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

November 19, 2024

Kura Oncology Reports Third Quarter 2024 Financial Results

November 6, 2024

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

November 4, 2024

Kura Oncology to Report Third Quarter 2024 Financial Results

October 30, 2024

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

October 23, 2024

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

October 22, 2024

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

September 29, 2024

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

September 16, 2024

Kura Oncology to Participate in Cantor Global Healthcare Conference

September 9, 2024

Kura Oncology Reports Second Quarter 2024 Financial Results

August 7, 2024

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

August 7, 2024

Kura Oncology to Report Second Quarter 2024 Financial Results

July 31, 2024

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

June 23, 2024

Kura Oncology to Participate in Jefferies Global Healthcare Conference

May 28, 2024

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

May 13, 2024

Kura Oncology Reports First Quarter 2024 Financial Results

May 1, 2024

Kura Oncology to Report First Quarter 2024 Financial Results

April 24, 2024

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

April 21, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

March 5, 2024

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

February 25, 2024

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

February 19, 2024

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

January 29, 2024

Kura Oncology Announces Oversubscribed $150 Million Private Placement

January 23, 2024

Calls in 2024

Decks in 2024